analogue 5c were totally resistant to the adenosine deaminase like iso-ddA (1). From the molecular modeling study the hydroxymethyl side chains of BMS-200475 (3) and 4c were almost overlapped, indicating that 4c may be suitable for phosphorylation by cellular kinases like the lead 3, but some discrepancy between two bases was observed, indicating why 4c is less potent against HBV than 3. It is concluded
基于领先的BMS-200475(3),设计并合成了具有环外亚
甲基的新型(2R,4R)-和(2S,4S)-异双
脱氧核苷(3),该化合物具有较强的抗HBV活性。为了合成D型的(2R,4R)-核苷,将
L-木糖转化为关键
中间体14。将
中间体14转化为尿
嘧啶衍
生物4a和
胞嘧啶衍
生物4b。化合物14也被转化为
嘌呤衍
生物,例如
腺嘌呤衍
生物4c,
次黄嘌呤衍
生物4d和
鸟嘌呤衍
生物4e。由市售的1,2-异亚丙基-
D-木糖(20)比(2R,4R)-核苷的合成方法更有效地合成了相应的L类型的(2S,4S)-对映异构体。将关键
中间体25转化为
嘧啶类似物5a和5b以及
嘌呤衍
生物5c,5d,和5e使用与制备4c,4d和4e相似的方法。测试了合成的最终(2R,4R)-和(2S,4S)-核苷对几种病毒(如HIV-1,HSV-1,HSV-2,HCMV和HBV)的测试。(2R,4R)-
腺嘌呤类似物4c在测试的化合物中表现出有效的抗HBV活性(
EC(50)=